|
시장보고서
상품코드
1553615
갑상선 질환 치료 시장 규모, 점유율, 동향 분석 리포트 : 적응증별, 약제별, 유통 채널별, 투여 경로별, 지역별, 부문별 예측(2024-2030년)Thyroid Gland Disorder Treatment Market Size, Share & Trends Analysis Report By Indication (Hypothyroidism), By Drug (Levothyroxine), By Distribution Channel, By Route of Administration, By Region, And Segment Forecasts, 2024 - 2030 |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
갑상선 질환 치료 시장의 성장과 동향 :
세계의 갑상선 질환 치료 시장 규모는 2030년에 28억 4,000만 달러에 달할 것으로 예측되며, 2024-2030년 CAGR 3.6%로 성장할 것으로 예측됩니다.
전 세계에서 갑상선 질환의 유병률이 증가함에 따라 향후 수년간 항갑상선제에 대한 수요가 증가할 것으로 예상됩니다. 갑상선기능저하증은 미국내 주요 입원 원인 중 하나이며, 의료 전문가와 환자들 사이에서 질병 관리에 대한 인식이 높아진 것도 시장 성장에 영향을 미칠 것으로 보입니다. 영국 갑상선 재단(British Thyroid Foundation), 미국 갑상선 협회(ATA), 캐나다 갑상선 재단(Thyroid Foundation of Canada) 등 다양한 민간 및 공공 단체가 질병 관리에 대한 인식을 높이기 위해 노력하고 있습니다.
이러한 의약품에 대한 수요 증가는 갑상선 질환을 치료하기 위해 브랜드 의약품의 다양한 제네릭 의약품 개발로 이어졌습니다. 제네릭 제약사들은 신제품 개발, 유통 채널 강화, 지역 확대, 타사 제품과의 제휴 등 경쟁 우위를 확보하기 위한 전략에 집중하고 있습니다. 또한 오리지널 의약품의 제네릭 의약품을 승인하는 규제 당국은 제품 승인 지연을 극복하고 이러한 의약품을 더 저렴한 가격으로 이용할 수 있도록 노력하고 있습니다. 이는 예측 기간 중 시장을 촉진할 것으로 예상됩니다.
갑상선 질환 치료 시장 보고서 - 하이라이트
- 갑상선기능저하증은 2023년 68.7% 시장 점유율을 차지하며 시장을 장악할 것으로 예상되며, 예측 기간 중 그 지위를 유지할 것으로 예상됩니다. 반면, 갑상선기능항진증은 갑상선기능항진증 유병률 증가로 인해 꾸준한 성장세를 보일 것으로 예상됩니다.
- 경구 투여는 편리함과 간편함으로 인해 환자의 순응도를 높이는 데 기여하므로 가장 선호되거나 가장 자주 사용되는 투여 경로입니다. 경구용 항갑상선제의 강력한 파이프라인의 존재가 시장을 주도하고 있습니다.
- 전체 헬스케어 지출과 함께 외래 처방약에 대한 지출이 증가함에 따라 도매 유통이 2023년 46.7%로 가장 큰 시장 매출 점유율을 차지했으며, E-Commerce는 향후 수년간 유리한 성장세를 보일 것으로 예상됩니다.
- 아시아 국가, 특히 인도와 중국은 향후 수년간 괄목할 만한 성장이 예상됩니다.
- 시장은 세분화되어 있고, 크고 작은 제약회사들이 존재합니다.
목차
제1장 조사 방법과 범위
제2장 개요
제3장 갑상선 질환 치료 시장의 변수, 동향, 범위
- 시장 서론/계통 전망
- 시장 규모와 성장 전망
- 시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
- 갑상선 질환 치료 시장 분석 툴
- Porter의 산업 분석
- PESTEL 분석
제4장 갑상선 질환 치료 시장 : 적응증별 추정·동향 분석
- 부문 대시보드
- 갑상선 질환 치료 시장 : 적응증 변동 분석, 2023년 및 2030년
- 갑상선 기능 저하증
- 갑상선 기능 항진증
제5장 갑상선 질환 치료 시장 : 약제별 추정·동향 분석
- 부문 대시보드
- 갑상선 질환 치료 시장 : 약제별 변동 분석, 2023년 및 2030년
- Levothyroxine
- Liothyroxine
- Propylthiouracil
- 이미다졸계 화합물
- 기타
제6장 갑상선 질환 치료 시장 : 유통 채널별 추정·동향 분석
- 부문 대시보드
- 갑상선 질환 치료 시장 : 유통 채널 변동 분석, 2023년 및 2030년
- 도매 판매
- 소매 판매
- 온라인 약국
제7장 갑상선 질환 치료 시장 : 투여 경로별 추정·동향 분석
- 부문 대시보드
- 갑상선 질환 치료 시장 : 투여 경로별 변동 분석, 2023년 및 2030년
- 경구
- 정맥내
제8장 갑상선 질환 치료 시장 : 지역별 추정·동향 분석
- 갑상선 질환 치료 시장 점유율, 지역별, 2023년 및 2030년
- 북미
- 미국
- 캐나다
- 멕시코
- 유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
- 아시아태평양
- 일본
- 중국
- 인도
- 한국
- 태국
- 라틴아메리카
- 브라질
- 아르헨티나
- 중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트
제9장 경쟁 구도
- 주요 시장 참여 기업에 의한 최근 동향과 영향 분석
- 기업 분류
- 기업 히트맵 분석
- 기업 개요
- Abbvie Inc.
- Amgen Inc.
- GSK Plc
- Merck KGaA
- Viatris Inc.
- Novartis AG
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited
- Elexis Inc.
- IBSA Pharma(IBSA Group)
Thyroid Gland Disorder Treatment Market Growth & Trends:
The global thyroid gland disorder treatment market size is expected to reach USD 2.84 billion in 2030 and is projected to grow at a CAGR of 3.6% from 2024 to 2030. An increase in the prevalence of thyroid diseases around the globe is expected to drive demand for anti-thyroid drugs in the coming years. Hypothyroidism is one of the leading causes of hospitalization in U.S. Growing awareness about disease management amongst healthcare professionals and patients is another factor augmenting the market growth. There are various private and public organizations working toward spreading awareness related to disease management, such as the British Thyroid Foundation, The American Thyroid Association (ATA), and Thyroid Foundation of Canada.
Rising demand for these drugs has resulted in the development of various generic equivalents of branded drugs to treat thyroid gland disorders. Generic drug manufacturers are focusing on strategies such as new product development, distribution channel enhancement, regional expansions, and collaborations with other companies for marketing their products to gain an edge over the competition. In addition, regulatory authorities that approve generic versions of branded drugs are working to overcome delays in product approvals and enable the availability of these drugs at a lower price. This is expected to boost the market over the forecast period.
Thyroid Gland Disorder Treatment Market Report Highlights:
- Hypothyroidism dominated the market and accounted for a market share of 68.7% in 2023 and is expected to maintain its position throughout the forecast period. On the other hand, hyperthyroidism is expected to witness steady growth on account of the increase in the incidence of Graves' disease
- The oral route is the most preferred or most frequently used route of administration owing to its convenience and simplicity, which helps improve patient compliance. The market is driven by the presence of a strong pipeline of oral anti-thyroid medications
- Wholesale distribution accounted for the largest market revenue share of 46.7% in 2023 owing to increasing spending on outpatient prescription drugs along with overall healthcare expenditure. E-commerce is expected to witness lucrative growth in the coming years
- Asian countries, especially India and China, are expected to observe remarkable growth in the coming years
- The market is fragmented in nature, with the presence of various large and small pharmaceutical players
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Thyroid Gland Disorder Treatment Market Variables, Trends, & Scope
- 3.1. Market Introduction/Lineage Outlook
- 3.2. Market Size and Growth Prospects (USD Million)
- 3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
- 3.4. Thyroid Gland Disorder Treatment Market Analysis Tools
- 3.4.1. Porter's Analysis
- 3.4.1.1. Bargaining power of the suppliers
- 3.4.1.2. Bargaining power of the buyers
- 3.4.1.3. Threats of substitution
- 3.4.1.4. Threats from new entrants
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Economic and Social landscape
- 3.4.2.3. Technological landscape
- 3.4.2.4. Environmental landscape
- 3.4.2.5. Legal landscape
- 3.4.1. Porter's Analysis
Chapter 4. Thyroid Gland Disorder Treatment Market: Indication Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Thyroid Gland Disorder Treatment Market: Indication Movement Analysis, 2023 & 2030 (USD Million)
- 4.3. Hypothyroidism
- 4.3.1. Hypothyroidism Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.4. Hyperthyroidism
- 4.4.1. Hyperthyroidism Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Thyroid Gland Disorder Treatment Market: Drug Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Thyroid Gland Disorder Treatment Market: Drug Movement Analysis, 2023 & 2030 (USD Million)
- 5.3. Levothyroxine
- 5.3.1. Levothyroxine Thyroid Gland Disorder Treatment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4. Liothyroxine
- 5.4.1. Liothyroxine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5. Propylthiouracil
- 5.5.1. Liothyroxine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.6. Imidazole-based compounds
- 5.6.1. Imidazole-based compounds Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.7. Others
- 5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Thyroid Gland Disorder Treatment Market: Distribution Channel Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Thyroid Gland Disorder Treatment Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
- 6.3. Wholesale Distribution
- 6.3.1. Wholesale Distribution Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4. Retail Sales
- 6.4.1. Retail Sales Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5. Online Pharmacy
- 6.5.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Thyroid Gland Disorder Treatment Market: Route of Administration Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Thyroid Gland Disorder Treatment Market: Route of Administration Movement Analysis, 2023 & 2030 (USD Million)
- 7.3. Oral
- 7.3.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4. Intravenous
- 7.4.1. Intravenous Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Thyroid Gland Disorder Treatment Market: Regional Estimates & Trend Analysis
- 8.1. Thyroid Gland Disorder Treatment Market Share, By Region, 2023 & 2030 (USD Million)
- 8.2. North America
- 8.2.1. North America Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.2. U.S.
- 8.2.2.1. U.S. Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.3. Canada
- 8.2.3.1. Canada Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.4. Mexico
- 8.2.4.1. Mexico Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3. Europe
- 8.3.1. Europe Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.2. UK
- 8.3.2.1. UK Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.3. Germany
- 8.3.3.1. Germany Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.4. France
- 8.3.4.1. France Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.5. Italy
- 8.3.5.1. Italy Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.6. Spain
- 8.3.6.1. Spain Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.7. Denmark
- 8.3.7.1. Denmark Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.8. Sweden
- 8.3.8.1. Sweden Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.9. Norway
- 8.3.9.1. Sweden Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4. Asia Pacific
- 8.4.1. Asia Pacific Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.2. Japan
- 8.4.2.1. Japan Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.3. China
- 8.4.3.1. China Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.4. India
- 8.4.4.1. India Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.5. South Korea
- 8.4.5.1. South Korea Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.6. Thailand
- 8.4.6.1. Thailand Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5. Latin America
- 8.5.1. Latin America Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.2. Brazil
- 8.5.2.1. Brazil Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.3. Argentina
- 8.5.3.1. Argentina Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6. Middle East and Africa
- 8.6.1. Middle East and Africa Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.2. South Africa
- 8.6.2.1. South Africa Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.3. Saudi Arabia
- 8.6.3.1. Saudi Arabia Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.4. UAE
- 8.6.4.1. Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.5. Kuwait
- 8.6.5.1. Kuwait Thyroid Gland Disorder Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Recent Developments & Impact Analysis by Key Market Participants
- 9.2. Company Categorization
- 9.3. Company Heat Map Analysis
- 9.4. Company Profiles
- 9.4.1. Abbvie Inc.
- 9.4.1.1. Participant's Overview
- 9.4.1.2. Financial Performance
- 9.4.1.3. Product Benchmarking
- 9.4.1.4. Recent Developments/ Strategic Initiatives
- 9.4.2. Amgen Inc.
- 9.4.2.1. Participant's Overview
- 9.4.2.2. Financial Performance
- 9.4.2.3. Product Benchmarking
- 9.4.2.4. Recent Developments/ Strategic Initiatives
- 9.4.3. GSK Plc
- 9.4.3.1. Participant's Overview
- 9.4.3.2. Financial Performance
- 9.4.3.3. Product Benchmarking
- 9.4.3.4. Recent Developments/ Strategic Initiatives
- 9.4.4. Merck KGaA
- 9.4.4.1. Participant's Overview
- 9.4.4.2. Financial Performance
- 9.4.4.3. Product Benchmarking
- 9.4.4.4. Recent Developments/ Strategic Initiatives
- 9.4.5. Viatris Inc.
- 9.4.5.1. Participant's Overview
- 9.4.5.2. Financial Performance
- 9.4.5.3. Product Benchmarking
- 9.4.5.4. Recent Developments/ Strategic Initiatives
- 9.4.6. Novartis AG
- 9.4.6.1. Participant's Overview
- 9.4.6.2. Financial Performance
- 9.4.6.3. Product Benchmarking
- 9.4.6.4. Recent Developments/ Strategic Initiatives
- 9.4.7. Pfizer Inc.
- 9.4.7.1. Participant's Overview
- 9.4.7.2. Financial Performance
- 9.4.7.3. Product Benchmarking
- 9.4.7.4. Recent Developments/ Strategic Initiatives
- 9.4.8. Takeda Pharmaceutical Company Limited
- 9.4.8.1. Participant's Overview
- 9.4.8.2. Financial Performance
- 9.4.8.3. Product Benchmarking
- 9.4.8.4. Recent Developments/ Strategic Initiatives
- 9.4.9. Elexis Inc.
- 9.4.9.1. Participant's Overview
- 9.4.9.2. Financial Performance
- 9.4.9.3. Product Benchmarking
- 9.4.9.4. Recent Developments/ Strategic Initiatives
- 9.4.10. IBSA Pharma (IBSA Group)
- 9.4.10.1. Participant's Overview
- 9.4.10.2. Financial Performance
- 9.4.10.3. Product Benchmarking
- 9.4.10.4. Recent Developments/ Strategic Initiatives
- 9.4.1. Abbvie Inc.
